Drugs / Quadrivalent influenza vaccine
Quadrivalent influenza vaccine
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Rejected (CRL) | US (FDA) | — | influenza | 2026-02-10 | “for its investigational influenza vaccine, mRNA-1010, and has issued a Refusal-to-File (RTF) letter” q4web.com ↗ |
| Filed | EU (EMA) | — | influenza | 2026-01-05 | “Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010” q4web.com ↗ |
| Filed | US (FDA) | — | influenza | 2026-01-05 | “Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010” q4web.com ↗ “mRNA-1010 has now been accepted for review in the United States” q4web.com ↗ |
Trials 24
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04363359 | Jan 2020 → Sep 2021 | influenza | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 2 | NCT03336593 | Nov 2017 → Mar 2018 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 314 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT06049927 | Sep 2023 → May 2024 | influenza | Sinovac Biotech Co., Ltd | Completed | Met primary |
| Phase 3 | NCT05245552 | Aug 2022 → Aug 2023 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT04848467 | Oct → Nov 2021 | COVID-19 | Bayer | Withdrawn | No outcome recorded |
| Phase 3 | NCT04544267 | Sep 2020 → Jun 2021 | influenza | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT04210349 | Jan → Dec 2020 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04001504 | Jul 2019 → Aug 2022 | acute coronary syndrome | Hospital Israelita Albert Einstein | Completed | Missed primary |
| Phase 3 | NCT03765437 | Jan → Mar 2019 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03744104 | Oct 2018 → Oct 2019 | influenza | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 3 | NCT03859141 | Feb → Apr 2018 | influenza | Sinovac Biotech Co., Ltd | Completed | Mixed |
| Phase 3 | NCT03853993 | Jan → Aug 2018 | influenza | Sinovac Biotech Co., Ltd | Completed | Met primary |
| Phase 3 | NCT02710409 | Jan → Jun 2016 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT01967784 | Oct 2013 → Apr 2014 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT01481454 | Mar → Oct 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT01240746 | Nov 2010 → Dec 2011 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 48 trials · 1 met primary | ||||||
| Phase 4 | NCT05970887 | Oct → Dec 2022 | — | Catholic Kwandong University | Completed | No outcome recorded |
| Phase 4 | NCT05996549 | Sep 2022 → Jul 2024 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 4 | NCT05471531 | Nov 2021 → Mar 2022 | — | Sinovac Biotech Co., Ltd | Completed | Met primary |
| Phase 4 | NCT05499351 | Oct → Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT04997239 | Oct 2021 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05313893 | Sep → Dec 2021 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT04801888 | Mar → May 2021 | COVID-19, influenza | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04667117 | Jan 2021 → Jul 2023 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT05227001 Comparator | Apr 2022 → Aug 2023 | influenza | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02860039 Comparator | Sep 2016 → Dec 2021 | cancer, disease related to hematopoietic stem cell transplant, influenza | Vanderbilt-Ingram Cancer Center | Completed | Met primary |
| Phase 3 | NCT05513391 Comparator | Nov 2022 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT05540522 Comparator | Sep 2022 → Mar 2024 | influenza | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01964989 Comparator | Nov 2013 → Oct 2015 | influenza | Seqirus | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 47
| Date | Issuer | Release |
|---|---|---|
| 2026-09-01 | GlaxoSmithKline | Results GSK to advance mRNA seasonal flu vaccine candidate to phase III following positive phase II data gsk.com ↗
GSK’s vaccine candidate showed higher immune responses against all influenza strains tested compared to licensed standard dose and high dose inactivated flu vaccines in younger and older adults respectively, and was generally well tolerated. |
| 2026-08-05 | ModernaTX, Inc. | Regulatory Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA q4web.com ↗
Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. |
| 2026-06-18 | ModernaTX, Inc. | Regulatory Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine q4web.com ↗ |
| 2026-05-13 | CSL Behring | Results Published Large U.S. Study Finds Comparable Effectiveness Between Adjuvanted and High-Dose Influenza Vaccines in Adults 65 Years and Older csl.com ↗
Adjuvanted and high-dose influenza vaccines did not differ in effectiveness against laboratory-confirmed influenza in any setting or influenza with emergency department visits or hospitalization. |
| 2026-05-06 | ModernaTX, Inc. | Results Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 q4web.com ↗
Moderna, Inc. (NASDAQ:MRNA) today announced a publication in the New England Journal of Medicine of the positive Phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. |
| 2026-04-06 | ModernaTX, Inc. | Results Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 q4web.com ↗
Additionally, there were no increases in solicited adverse reactions or new safety concerns observed with sequential mRNA-1010 vaccination. |
| 2026-02-18 | ModernaTX, Inc. | Regulatory Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission q4web.com ↗
Following submission of the amended application, the FDA has accepted the biologics license application (BLA) for review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 5, 2026. |
| 2026-02-13 | ModernaTX, Inc. | Regulatory Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates q4web.com ↗
Announces influenza vaccine filing accepted for regulatory review in the EU, Canada and Australia; Company received Refusal-to-File letter from U.S. FDA and has requested Type A meeting to understand path forward |
| 2026-02-10 | ModernaTX, Inc. | Regulatory Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 q4web.com ↗
CBER's RTF letter, signed by Center Director Vinayak Prasad, MD, MPH, identified the choice of a licensed standard-dose seasonal influenza vaccine comparator as the sole reason for the refusal to initiate the review of Moderna's application. |
| 2026-01-05 | ModernaTX, Inc. | Regulatory Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine q4web.com ↗
The Company has filed for marketing authorization with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the Therapeutic Goods Administration (TGA) in Australia. |
| 2025-10-19 | ModernaTX, Inc. | Results Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 q4web.com ↗
rVE was 26.6% (95%CI: 16.7%, 35.4%) in the overall study population, meeting the prespecified superiority criteria. |
| 2025-08-14 | Sinovac Biotech Co., Ltd | Results 《免疫学前沿》刊文：科兴四价流感疫苗与23价肺炎疫苗在老年慢病人群中同时接种具有良好的免疫原性和安全性 sinovac.com ↗ |
| 2025-07-10 | Osivax | Results Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal osivax.com ↗
Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix® Tetra) was well-tolerated and demonstrated a favorable safety profile |
| 2025-06-30 | ModernaTX, Inc. | Results Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine q4web.com ↗
mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population. |
| 2025-05-13 | Sinovac Biotech Co., Ltd | Regulatory 科兴集团三价和四价流感疫苗同时在香港特区获批注册 sinovac.com ↗
2025年5月8日，由北京科兴控股（集团）有限公司（以下简称“科兴集团”）旗下北京科兴生物制品有限公司生产的三价流感病毒裂解疫苗安尔来福 ® 和四价流感病毒裂解疫苗获得香港特区药品监管机构签发的《药品/制品注册证明书》。 |
| 2024-09-12 | ModernaTX, Inc. | Results Moderna R&D Day Highlights Progress and Strategic Priorities q4web.com ↗
In an older adult extension study of P303, mRNA-1010 met all primary immunogenicity endpoints-including superiority for all strains-compared to a licensed enhanced flu vaccine (Fluzone HD®) and showed an acceptable reactogenicity profile. |
| 2024-09-05 | Sinovac Biotech Co., Ltd | Results SINOVAC科兴四价流感疫苗与23价肺炎疫苗在60岁及以上老年人中同时接种具有良好的安全性和免疫原性 sinovac.com ↗ |
| 2024-08-23 | Sinovac Biotech Co., Ltd | Results 最新研究：SINOVAC科兴四价流感疫苗抗体滴度高于国外对照疫苗 sinovac.com ↗ |
| 2024-08-09 | Sinovac Biotech Co., Ltd | Results 研究表明：SINOVAC科兴四价流感疫苗批间一致性好，疫苗品质稳定可靠 sinovac.com ↗
研究结果表明，SINOVAC科兴连续三批商业化规模生产的IIV4具有良好的免疫原性和安全性，且各型别抗体水平相当，产品批间一致性好。 |
| 2023-10-27 | Sinovac Biotech Co., Ltd | Results 研究显示：3-8岁儿童接种2针流感疫苗能获得更佳保护 sinovac.com ↗
在既往未接种过或接种过一剂次流感疫苗的儿童中，接种两剂次IIV4的血清保护率要高于接种一剂次IIV4的血清保护率。 |
| 2023-09-18 | CSL Behring | Results CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources csl.com ↗
Findings from a dynamic transmission model indicated that standard-dose quadrivalent influenza vaccines for this demographic could reduce hospitalizations by 11.1%-30.0% and ICU admissions by 9.7%-28.7%. |
| 2023-09-13 | ModernaTX, Inc. | Results Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease q4web.com ↗
Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HD Vaccine |
| 2023-08-11 | Sinovac Biotech Co., Ltd | Results 最新研究：科兴四价流感疫苗与23价肺炎疫苗在60岁及以上老年人中同时接种具有良好的安全性 sinovac.com ↗
这项由江苏泰州疾控中心研究人员开展的研究显示， 北京科兴生物制品有限公司的四价流感病毒裂解疫苗与23价肺炎球菌多糖疫苗在60岁及以上老年人中同时接种具有良好的安全性 [1] 。 |
| 2023-05-09 | Novavax | Results Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses novavax.com ↗
The stand-alone influenza vaccine candidate achieved statistically significant hemagglutination inhibition (HAI) antibody responses 31 to 56% higher for all four strains compared to Fluad. |
| 2023-04-11 | ModernaTX, Inc. | Results Moderna Announces Clinical and Program Updates at 4th Vaccines Day q4web.com ↗
Company's first influenza candidate, mRNA-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the independent DSMB recommended continuation of efficacy follow-up |
| 2023-02-16 | ModernaTX, Inc. | Results Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate q4web.com ↗
Interim results indicate that mRNA-1010 achieved superiority on seroconversion rates for A/H3N2 and A/H1N1, as well as superiority on geometric mean titer ratios for A/H3N2 and non-inferiority on geometric mean titer ratios for A/H1N1. |
| 2022-09-26 | CSL Behring | Results New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems csl.com ↗
CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing the burden of seasonal influenza on hospitals and health systems. |
| 2022-03-24 | ModernaTX, Inc. | Results Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day q4web.com ↗ |
| 2021-12-10 | ModernaTX, Inc. | Results Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update q4web.com ↗
In the study, mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults. |
| 2021-12-07 | CSL Behring | Results New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults csl.com ↗
In this study, findings demonstrated that aTIV was associated with 12% lower risk of hospitalization and a 37% lower risk of respiratory-related hospitalizations compared with TIV and QIV. |
| 2021-10-14 | CSL Behring | Results The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to < 18 Years of Age csl.com ↗
today announced that The New England Journal of Medicine has published absolute efficacy data on the company’s cell-based quadrivalent influenza vaccine (QIVc) from a randomized controlled trial (RCT) which met its primary endpoint. |
| 2021-10-07 | Sanofi | Results Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations sanofi.com ↗
This is the first study to provide supportive evidence for vaccinating against influenza at the same time as a COVID-19 mRNA booster in seniors. |
| 2021-09-29 | Pfizer | Results Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released pfizer.com ↗
Responses elicited by PREVNAR 20 for all 20 serotypes and by seasonal influenza vaccine when given together were noninferior (the study’s primary immunogenicity objectives) to those elicited by the vaccines when administered one month apart. |
| 2020-12-14 | CSL Behring | Results Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020 csl.com ↗
A Late-breaking poster presentation demonstrating that QIVc prevented significantly more influenza-related medical encounters among individuals aged ≥4 years (n=2,113,216) with at least one health condition, compared to QIVe in the 2018/19 U.S. influenza season. |
| 2020-12-14 | CSL Behring | Results Seqirus Presents New Late-Breaking Data at ESWI 2020 Highlighting Value of MF59®-Adjuvanted Seasonal Influenza Vaccine csl.com ↗
Results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters.1 |
| 2020-11-18 | Sanofi | Regulatory European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older sanofi.com ↗
The European Commission has granted a marketing authorization for Supemtek ® , a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older. |
| 2020-09-22 | Sanofi | Regulatory CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older sanofi.com ↗
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Supemtek® (recombinant influenza vaccine) for active immunization for the prevention of influenza in adults. |
| 2020-06-08 | CSL Behring | Regulatory First adjuvanted quadrivalent influenza vaccine receives EU approval csl.com ↗
The European Commission has today given regulatory approval for the first adjuvanted quadrivalent influenza vaccine to become available across Europe. |
| 2020-03-31 | CSL Behring | Regulatory Seqirus announces positive CHMP Opinion for its adjuvanted quadrivalent influenza vaccine csl.com ↗ |
| 2019-12-11 | CSL Behring | Regulatory Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine csl.com ↗
Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. |
| 2019-08-31 | CSL Behring | Results Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses csl.com ↗
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses. |
| 2019-08-30 | CSL Behring | Results Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response csl.com ↗
Induced a higher immune response upon two revaccination studies as demonstrated for both homologous and heterologous strains in children (6 months to 72 months old) compared to a non-adjuvanted influenza vaccine |
| 2019-01-14 | CSL Behring | Regulatory First cell-based quadrivalent influenza vaccine approved for use in Europe csl.com ↗
Seqirus, a global leader in influenza prevention, today announced that the European Commission has issued marketing approval for its new cell-based seasonal influenza vaccine, FLUCELVAX® TETRA▼ [influenza vaccine (surface antigen, inactivated, prepared in cell cultures)]. |
| 2018-12-05 | CSL Behring | Results Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season csl.com ↗
The rVE estimated from the study’s primary analysis indicated that QIVc was more effective than standard egg-based QIVs in preventing ILI (rVE of 36.2%, 95% CI (26.1,44.9; P<0.001)). |
| 2018-11-16 | CSL Behring | Results Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options csl.com ↗
Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccine (QIVe) in preventing influenza-like illness (ILI) captured within primary care visits in people aged 4 years and above during the 2017/18 influenza season in the United States, a season characterized by egg-adapted changes. |
| 2018-03-06 | GlaxoSmithKline | Results New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age gsk.com ↗
The study met its two primary endpoints, demonstrating 63.2% (97.5% CI: 51.8–72.3) vaccine efficacy against laboratory-confirmed moderate-to-severe influenza, and 49.8% (97.5% CI: 41.8–56.8) vaccine efficacy against influenza of any severity in children six to 35 months of age. |
| 2017-10-23 | CureVac | Results Publikation in npj Vaccines beschreibt Vorteile mRNA-basierter Impfstoffe gegenüber zugelassenen Impfstoffe curevac.com ↗
Die Studie “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” von Lutz et al. demonstriert erstmals, dass eine einzelne intramuskuläre Grippe- oder Tollwutimpfung mit LNP-formulierter, chemisch unveränderter mRNA im Tiermodell starke Immunantworten induziert. |
All press releases naming this drug 47 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 33 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Influenza Vaccine | “the quadrivalent influenza vaccine and the 23-valent pneumococcal polysaccharide vaccine(PPV23) were manufactured by Sinovac Biotech Co.” NCT05499351 ↗ |
| Known as | IIV4 | “Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains and one strain from each B lineage (Yamagata and Victoria) may offer broader protection...” PMID 25843270 ↗ Apr 20153“Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains (H1N1 and H3N2) and one strain from each B lineage (Victoria and Yamagata)” PMID 32732142 ↗ Jul 2020 “non-adjuvanted inactivated influenza vaccine (ie, trivalent inactivated influenza vaccine [IIV3] or quadrivalent inactivated influenza vaccine [IIV4])” PMID 29631857 ↗ Apr 2018 “Biological: Quadrivalent influenza vaccine (IIV4)” NCT05513391 ↗ |
| Known as | QIV | “The aim of the study is to assess the safety profile of a quadrivalent influenza vaccine (QIV) and to demonstrate that 3 different industrial lots of QIV induce an equivalent...” NCT01481454 ↗5“Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)” NCT01964989 ↗ “new formulation of Quadrivalent Influenza Vaccine (QIV) for the 2013-2014 season” NCT01967784 ↗ “flu vaccine called seasonal quadrivalent influenza vaccine (QIV)” NCT04848467 ↗ “licensed quadrivalent influenza vaccine (QIV)” NCT05540522 ↗ “Quadrivalent influenza vaccine (QIV)” NCT05227001 ↗ |
| Known as | QIV-HD | “high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD)” NCT04544267 ↗ |
| Known as | QIV-SD | “high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD)” NCT04544267 ↗ |
| Known as | SD-QIV | “We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025 |
| Known as | standard-dose quadrivalent influenza vaccine | “We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025 |
| Modality | Vaccine | “Quadrivalent Influenza Vaccine, No Preservative” NCT01240746 ↗ |
| Route | Intramuscular | “0.25 mL (6 to 35 months), or 0.5 mL(3 to \<9 years), Intramuscular” NCT01240746 ↗ |